November 06, 2024

Alzheimer's Trial Reports Unexpected Drug Effects

The trial found that deferiprone decreased brain iron but unexpectedly accelerated cognitive decline in Alzheimer's patients, with a higher cognitive decline rate (-0.80 vs -0.30 composite z score) compared to placebo, challenging long-held assumptions about iron's role in neurodegeneration.

Conexiant